Received a Bachelor's degree from the Department of Chemistry, Fudan University in 1992, joining its faculty the same year.
Obtained a Master's degree from the Department of Chemistry, Fudan University in 1997, and a Ph.D. from the Department of Chemistry, Fudan University in 2003.
Laboratory and Team Development
We have acquired fundamental research instruments including high-performance liquid chromatography, liquid chromatography-mass spectrometry, preparative chromatography, ultra-low temperature reactors, PCR instruments, fluorescence spectrometers, adsorption instruments, powder diffractometers, etc. We have also introduced a complete set of research management software, achieving interactive cloud-based management of research data.
The team consists of 8 full-time faculty members, including 2 professors, 3 associate professors, 1 associate researcher, and 2 senior engineers. The disciplines covered include organic chemistry, physical chemistry, inorganic chemistry, and structural chemistry.
The team maintains good cooperative relationships with senior professionals from domestic and international universities, research institutions, and pharmaceutical companies. Focusing on new drug development and diagnostic/therapeutic materials, we have established a research team with professional skills and distinctive characteristics.
Research and Talent Cultivation
The team has undertaken or participated in numerous national research projects, including: National Key R&D Program, Major Program of National Natural Science Foundation of China, Ministry of Education Innovation Team Project, National Science and Technology Support Program, National Basic Research Program, and various National Natural Science Foundation projects.
The team has signed new drug development projects with several internationally renowned pharmaceutical R&D companies. Developed/in-development new drugs include: c-met, PIM, PI3K, BTK, IDO inhibitors, etc.
Among these, a small molecule drug for treating thyroid or kidney cancer, screened under commission, was approved by the FDA in 2012; commissioned by a company, a novel targeted tumor molecular drug has been screened and is currently in FDA Phase III clinical trials.
We have over 40 graduated students with 12 currently enrolled. Graduates include university faculty, corporate managers, industry leaders, etc.
